Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
April 24, 2024
RegMed Investors (RMi) Closing Bell: I told you so
April 23, 2024
RegMed Investors (RMi) Closing Bell: welcoming the upside trend
April 19, 2024
RegMed Investors (RMi) Closing Bell: a tough week; tied to cross-currents of geopolitical conflicts and recurring inflation
April 17, 2024
RegMed Investors (RMi) Closing Bell: start thinking of sector equities’ future direction without the geopolitical cloud overhead
April 10, 2024
RegMed Investors (RMi) Closing Bell: the cell and gene therapy sector got chewed-up, bloods everywhere
April 9, 2024
RegMed Investors’ (RMi) pre-open: WHAT and WHEN are the catalysts to move share pricing
April 2, 2024
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
April 1, 2024
RegMed Investors (RMi) Closing Bell: An early share pricing eclipse in first session of April?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors